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Multiple myeloma (MM) is a progressive B-lineage neoplasia characterized by clonal proliferation of malignant plasma cells.
IncreasednumbersofregulatoryTcells(Tregs)weredeterminedinmousemodelsandinpatientswithMM,whichcorrelatedwith
disease burden. Thus, it became rational to target Tregs for treating MM. The eﬀects of common chemotherapeutic drugs on Tregs
are reviewed with a focus on cyclophosphamide (CYC). Studies indicated that selective depletion of Tregs may be accomplished
following the administration of a low-dose CYC. We report that continuous nonfrequent administrations of CYC at low doses
block the renewal of Tregs in MM-aﬀected mice and enable the restoration of an eﬃcient immune response against the tumor
cells, thereby leading to prolonged survival and prevention of disease recurrence. Hence, distinctive time-schedule injections of
low-dose CYC are beneﬁcial for breaking immune tolerance against MM tumor cells.
1.Introduction
Multiple myeloma (MM) is a progressive B lineage neoplasia
characterized by clonal proliferation of malignant plasma
cells that localize in the bone marrow (BM) replacing
the normal BM population. A reduced level of polyclonal
immunoglobulins is a consistent feature of active MM
reﬂecting the suppression of CD19+ lymphocytes that corre-
lateinverselywiththediseasestage.Therelationshipbetween
myeloma plasma cells and the BM microenvironment is
critical for the maintenance of the disease. Tumor cells
and stromal cells interact via adhesion molecules and
cytokine networks to simultaneously promote progression of
the disease leading to bone destruction, vertebral collapse,
hypercalcemia, renal failure, hypogammaglobulinemia, and
peripheral neuropathy. The disease is associated with both
cellularandhumoralimmunedeﬁciencies[1].Recentstudies
have revealed that CD4+CD25highFoxp3+ regulatory T cells
(Tregs), which are physiologically engaged in the mainte-
nance of immunological self-tolerance, play critical roles for
the control of antitumor immune responses. Increased num-
bers of Tregs were documented in peripheral blood, tumor
mass, and draining lymph nodes from patients of a wide
spectrumofcancers.AstrongcorrelationexistsbetweenTreg
levels and the progression of cancer. The increased number
of Tregs was reported to reﬂect poor prognosis [2] and is
associated with suppression of T cell proliferation, down-
regulation of proinﬂammatory cytokines, and involvement
in tumor tolerance to self antigens. Thus, new anticancer
strategies involving interference in Treg biology by means of
functional disruption or numerical depletion are of critical
importance. Treg depletion can lead to decreased tumor
cell growth both directly by enabling anti cancer cytotoxic
eﬀects or indirectly by inducing cellular immune responses
against cancerous cells. General strategies to reduce Treg
functions include depletion of Tregs by chemotherapeutic
drugs, blockade of Treg function by target known receptors,
blockade of Treg traﬃcking, and combing depletion of Tregs
with tumor vaccination.
Recently, we showed a correlation between increased
ratiosoffunctionalTregsanddiseaseprogressioninaunique
mouse model of MM that mimics the human disease [3, 4].
Low-dose cyclophosphamide (CYC) that selectively depletes
Tregs reduced MM progression. Treatment of tumor-bearing2 Bone Marrow Research
mice with repeated administrations of low-dose CYC at
longer time intervals (coinciding with the blocked renewal
of Tregs) resulted in reduced tumor load and prevention or
delay of disease recurrence. The break of immune tolerance
against MM tumor cells by prolonged maintenance of
transient Treg depletion will be reviewed.
2. ImmuneAbnormalities inMM Patients
The number and function of T cells subsets are aberrant in
patients with MM [5, 6]. The CD4:CD8 ratio is inverted
and the helper T-cell type 1 to type 2 (Th1:Th2) ratio
among CD4 cells is abnormal [7]. In addition, the levels
of expression of CD28 costimulatory molecules required for
T cell activation are downregulated in T cells derived from
MM patients [8]. The elevated levels of transforming growth
factor (TGF)-β, in addition to the impaired accessory signals
from Th cells, contribute to the presence of dysfunctional
B cells [9]. Defective natural killer cells (NK) have also
been noted in MM patients [10]. Circulating dendritic cells
(DCs) from MM patients were shown to be dysfunctional,
failing to upregulate costimulatory molecules required for
DCs activation, which led to reduced phagocytic activity
and antigen presentation [11]. It was reported that the
impaired activity of DCs may be linked to the upregulation
of Tregs [12]. Interestingly, in vivo expansion of Tregs
could be induced in the presence of MM-speciﬁc antigens
in association with reduced immune eﬀector functions.
Immunologicallyactivecompoundsthatpromotetumor-cell
survival are produced by myeloma cells. The latter include
TGF-β, IL-10, IL-6, vascular endothelial angiogenic growth
factor (VEGF), Fas ligand, Mucin 1, cyclooxygenase (Cox)-
2, and related prostanoids and metalloproteins [13]. The
increased numbers of Treg and the impairment and mod-
ulation of immune functions in myeloma patients suggest
that breaking tolerance by chemoimmunotherapy involving
transient Treg depletion and recruitment of compatible
immune-derived cells could perhaps reduce tumor load and
delay or prevent tumor development.
3.CD4+CD25highFoxp3+ Tregs
Subpopulations of T cells with suppressive capacities against
antitumor activity of the immune system were ﬁrst described
in the early 1980s [14]. In the last decade, these subsets
of cells were found to be naturally occurring or adoptively
induced. They constitute 5–10% of na¨ ıve CD4+ T cells in the
periphery and are anergic cells with suppressive capabilities.
These cells are induced early during tumor development and
were shown to contribute to tumor tolerance [15]. These
cells were characterized as CD4 cells that express CD25 and
the transcription factor Foxp3 (forkhead/winged helix tran-
scription factor). The latter is essential for the suppressive
phenotype of the cells [16, 17]. Also, Tregs constitutively
express CTLA-4, and CTLA-4 deﬁciency in Tregs results
in enhanced antitumor immunity [18]. The mechanisms
underlying the suppressive eﬀects of Tregs include inhibiting
the activity of a variety of immune cells that are tumor
speciﬁc such as CD4 and CD8 cells, B cells, NK cells, natural
killer T cells (NKT), and DCs [19–21]. Both types of T cells,
CD4 and CD8 cells, are considered key components against
tumors [22, 23]. Further, NK cells destroy tumor cells that
have reduced the expression of MHC class I but still express
ligands for activating receptors of NK cells [24]. These cells
are prone to inhibition by Tregs, which might lead to the
continuation of tumor development and proliferation.
3.1. Tregs and Malignancy. Tregs, naturally occurring and
inducible, play a key role in the regulation of antitumor
immune response in patients with cancer. It was shown
that within the tumor microenvironment the tumor itself
inducesna¨ ıveCD4cellstoconvertintoantigen-speciﬁcTregs
[15]. Many of the immune cells that reside in the tumor
milieu are aﬀected by Tregs, and thus Tregs help tumors to
escape detection and elimination by the immune system. It
was shown that depletion of Tregs in tumor-bearing mice
resulted in the enhancement of antitumor immunity and
the reduction of tumor growth [25–29]. In patients with
ovarian cancer, the inﬁltration of CD3+ eﬀector T cells
was associated with a better prognosis [30], whereas the
accumulation of Tregs was suggestive of poor prognosis [2].
These observations were also conﬁrmed in non-small-cell
lung cancer [31]. The accumulated data strongly suggested
a new therapeutic strategy in the ﬁeld of cancer aimed at
eliminating Tregs or disrupting their activity.
3.2. Treg and MM. There is now suﬃcient evidence that
CD4+CD25highFoxp3+ Tregs actively impede the antitumor
immune response in cancer patients. In vivo peripheral
expansion of natural na¨ ıve CD4+CD25highFoxp3+ Tregs were
observed in large cohorts of 195 MM patients [32, 33].
Increased numbers of naturally occurring Tregs correlated
with disease burden (coinciding with paraprotein levels) and
increasedmorbidity.ThefrequencyofdoublenegativeTcells
(CD3+,C D 4 −, and CD8− αβTCR+)w a sr e d u c e di np a t i e n t s
with MM. CD4+CD25high T cells from MM patients were
shown to coexpress markers associated with Treg phenotype
such as CTLA-4, GITR, and CD69. High serum levels of
IL-10 and TGF-β were also observed. In both humans and
animal models of MM, Tregs have been described as anergic
cells, fully functional in early and late stage MM, exerting
strong suppression after T-cell receptor stimulation [34, 35].
Contradictory ﬁndings concerning Treg levels and activity in
MM patients were published by Prabhala et al. [36], namely,
reduced CD4+Foxp3+ T cells as well as Treg dysfunction,
indicating that Tregs were unable to suppress anti-CD3+
mediated T-cellproliferation. Whetherthesetestedcellswere
coexpressing CD25high was not determined in this study.
Notably, it seems that diﬀerences in research strategies may
account for the contradictory data in the area of MM
malignancy.
TheresponseofTregstotumorsisillustratedinmicethat
lackTregsandeﬀectivelyrejecttumors[26].Theinvolvement
of Tregs in MM progression was also studied in a unique
mouse model of MM (5T2MM) that developed sponta-
neously in BM of a very old mouse of the C57BL/KalwRij
strain [37, 38]. The tumor designated 5T2MM can beBone Marrow Research 3
CD4+CD25+Tregs
CD4+CD25+Tregs NKT cells
Mq
DCs
Tc e l l s
Bc e l l s
Plasma cells
1 45 90 135
CYC CYC CYC CYC
CD4
tregs
NKT cells
Window
opportunity
Injection
day
NKT
cells
Activation of DCs
Tc e l l s
Bc e l l s
Plasma cells
Low-dose CYC Stateofdisease
Figure 1: Cellular responses to low-dose CYC in mice with MM.
maintained only by transfer of BM cells from sick mice to
young syngeneic mice. The 5T2MM mouse model resembles
the human disease in its main localization to the BM and in
the development of hind limb paralysis (due to spinal cord
compression) that occurs as an early manifestation of the
disease. Further, as the disease progresses, signs of paraplegia
and bone lesions take place. Increased accumulation of Tregs
is observed in peripheral lymphoid organs, including lymph
nodes, BM, and peripheral blood during disease progression
[3, 4]. The suppressive functions of Tregs were retained,
indicating that the cells were functional in their capacity to
regulate immune activity. A correlation between increased
Treg levels and disease morbidity was observed. Adoptive
transfer of Tregs separated from thymuses of sick 5T2MM
mice into 5T2MM-bearing mice serving as Treg recipients,
increased severity of MM and enhanced tumor progression.
Severe bone destruction, fractures of vertebra, and massive
tumor cell inﬁltration into skeletal muscles were observed.
The transfer of Treg-free thymocytes did not mediate the
tumor-enhancing eﬀects [3]. These results clearly indicated
thatTregscanspeciﬁcallysupportinvivotumorprogression.
4. Common Chemotherapeutic Drugs
Affecting Treg Depletion
A number of chemotherapeutic agents that aﬀect Tregs are
usedforpreventingtumorprotectionbytheimmunesystem.
Gemcitabine is a nucleoside analogue that inhibits DNA
synthesis.Inpatientswithcoloncancerthatweretreatedwith
gemcitabine, the depletion of Tregs occurred concomitantly
with an increase in cytotoxic CD8 T cells [39]. However,
when this drug was administered in pancreatic cancer, it did
not deplete Tregs although it led to activation of na¨ ıve CD4
T cells [40]. Mitoxantrone is an anthracenedione that causes
DNA strand breakup and unraveling. Its administration to
patients with breast cancer resulted in reduced numbers of
Tregs, but this eﬀect was not correlative with the tumor
response [41]. Fludarabine is a drug used for treating
chronic lymphocytic leukemia (CLL). In vitro eﬀects of this
drug were the inhibition of Tregs expansion and sustaining
the potency of cytotoxic CD8 T cells [42]. Patients with
CLL treated with ﬂudarabine responded with a preferential
depletion of Tregs mainly as a result of apoptosis induction
[43]. Lenalidomide is a derivative of thalidomide that was
approved by the FDA for treating myelodysplastic syndrome
and MM. In vitro assays showed that lenalidomide aﬀected
Tregs by reducing their expansion and function [44]. CYC
is an alkylating agent that is commonly used in various
antitumor protocols. In addition to the general cytotoxic
eﬀects of CYC, it was reported that doses may inﬂuence
selectivity of this drug against Tregs. As a result, the clinical
relevance of CYC in oncologic therapy has become stronger.
Its use in this regard is discussed below.
5. CYC in Cancer Therapy
Therapeutic approaches for breaking tolerance towards
tumor cells have been studied extensively. The depletion of
Tregs is the most investigated strategy and CYC was found to
have speciﬁc eﬀects on T cells with tumor inhibiting proper-
ties[45].Intheliver,CYCisconvertedtotheactivemetabolic
aldophosphamideandphosphamidemustardswhichbindto
DNA, thereby inhibiting DNA replication and causing cell
death. CYC has a broad antitumor spectrum, a low niche
of inducing chemoresistance, and a limited hematopoietic
toxicity [46]. High doses of CYC have direct tumoricidal
eﬀects, cause immunosuppression by lymphoablation, and
is used also in the clinic with the primary aim of damping
ongoing immune responses in patients with autoimmune
diseases. Administration of low-dose CYC (in the range
of 20–150mg/kg body weight) can paradoxically augment
immune responses (demonstrated in many experimental
animal models) leading to immunostimulation. Low-dose
CYC acts on cycling Tregs and inhibits their suppressor
functionbyenhancingapoptosisanddecreasinghomeostatic
proliferation. The net outcome of CYC immunomodulation
depends on the balance between immune suppressive Treg
response and non-Treg eﬀector responses. Expression of4 Bone Marrow Research
GITR and Foxp3 which are involved in the suppressive
activity of Tregs is downregulated by CYC administration
[47]. Studies have shown the presence of a large number of
Foxp3+ Tregs in a variety of tumors and the enhancement of
naturalaswellasvaccine-inducedantitumorTcellresponses
by systematically or locally removing Foxp3+ Tregs [48]. A
single low-dose CYC causing Treg depletion was shown to
be curative by potentiating tumor-speciﬁc immunotherapy
against established tumors [49]. High doses of CYC were less
eﬀective in rejecting tumor growth [50]. Treatment of neu-N
mice with vaccine and low-dose CYC chemotherapy rejected
tumor challenge due to the recruitment of latent pools of
CD8+ cells to the antitumor immune response [51]. Mice
bearing poorly immunogenic B16 melanoma did not evoke
immunity; however, the depletion of CD4+CD25+Tregs
resulted in CD8+ T-cell mediated rejection of secondary
challenged B16 tumors [52]. CYC was shown to induce IFN-
α production, thereby augmenting lymphocyte proliferation
including CD44high memory T-cell phenotype that might
account for the increased antibody responses and the
persistence of memory cells [53]. Low-dose CYC, in addition
to its detrimental eﬀects on Tregs, was shown to augment
the antitumor immunogenicity of DC vaccine tested in B16
melanoma or C26 colon cancer [54].
Increased Tregs in the peripheral blood and tumor
microenvironment were observed in many human malig-
nancies.However,thecurrentclinicalapplicationofthelatter
in cancer chemoimmunotherapy is limited. Oral adminis-
tration of metronomic low-dose CYC regimen (100mg at
regular intervals) in advanced cancer patients induced a
profound and selective reduction of Tregs and restoration
of T-cell proliferation and innate killing activity by NK
eﬀector functions. An increased dose of CYC (200mg
taken daily) failed to deplete Tregs or to restore immune
functions [55]. These studies validated CYC ability to induce
transient Treg depletion in humans. The combination of
chemotherapy and immunotherapy was tested in advanced
pancreatic cancer patients. The vaccination was induced
using allogeneic GM-CSF secreting cell lines alone or in
sequencewithCYC(250mg/m2)beforevaccination.Further,
patients with metastatic pancreatic cancer treated with CYC
followedbyGM-CSFhadCD8+ TcellresponsestoHLAclass
I-restricted mesothelium epitope, and the patients’ survival
was prolonged [56].
A phase I clinical trial in patients with metastatic carci-
noma and a high Treg level in their peripheral blood tested
theeﬀectofasingleintravenousinfusionofCYCinthreedif-
ferentdoses(e.g.250,500,or700mg/m2)whenadministered
concomitantly with a nonspeciﬁc immunotherapy using
intratumoral Bacilli Calmette-Guerin (BCG). It was found
in this trial that CYC at the doses tested did not modulate
signiﬁcantly Treg numbers and function, and the authors
concluded that CYC may not represent an optimal therapy
for eliminating Tregs [57]. Nevertheless, it has been reported
(in many animal models) that only CYC at low doses (20–
150mg/kg body weight) could enhance immunostimulation
due to the selective killing of Tregs [4, 46, 47, 51]. Hence,
it should not come as a surprise that high doses of 500
and 700mg/m2 in the reported trial failed to reduce the
frequency of Tregs or to modulate their function; in fact,
the best reduction of Tregs in this trial was observed in
patients who were treated with the lowest dose of three
tested, for instance, 250mg/m2. In the metronomic regimen
studies [55], it also was stressed that only the low daily
oral dose of 100mg (in contrast to the nonactive 200mg
dose) selectively depleted Tregs cells. Another clinical trial
that followed after the frequency and function of Tregs
in patients with advanced hepatocellular carcinoma who
were treated with CYC at doses 150, 250, or 350mg/m2
on day 1 and day 29 found that only the lower doses of
CYC (150 and 250mg/m2) could impair Treg number and
function and unmask α-fetoprotein-speciﬁc T cell responses.
In fact, a better and more prolonged suppression of Treg
function was observed in patients treated with 250mg/m2.
In contrast, the reduction of Tregs in response to the high
CYC dose (350mg/m2) was not signiﬁcant [58]. There is
limited information about the kinetics and function of Tregs
following CYC induced transient Treg depletion (including
recovery to pretreatment levels) in patients with cancer. The
duration of the blocked renewal of Tregs following CYC
treatment might be important when considering repeated
administrations of low-dose CYC at longer intervals using
the window opportunity [4, 59].
5.1. Eﬀects of a Single Low- or High-Dose CYC on 5T2MM
Progression. High doses of CYC are eﬀective in tumor
therapy because of their direct cytotoxic eﬀect and inhibitory
activity against cycling cells, thus killing tumor cells but
along with the depletion of immune cells. In contrast, low
doses of the drug have been shown to selectively reduce
the number and function of Tregs and induce antitumor-
mediated eﬀects. Within 24 hours after CYC administration
to 5T2MM-bearing mice at the clinical phase of the disease
(60–70 days after tumor cell challenge), both low- and
high-dose CYC (100 and 200mg/kg body weight, resp.)
resulted in normalization of serum paraprotein level. In the
BM cavity, plasma tumor cells were replaced with normal
cell populations, in association with prolonged survival.
However, a higher MM incidence (80–85%) was observed
in those treated with the high-dose in comparison with the
low-dose CYC (40–50%) [4]. Further, mice treated not with
low-dose but with high-dose CYC still had residual 5T2MM
cells, because adoptive transfer of BM cells from grossly
appearing mice 170 days after initiation of treatment into
young syngeneic recipients resulted in the development of
disease in the BM of the latter 3-4 months afterwards [59].
Inhibitory eﬀects of CYC on Tregs have been shown
in previous studies [46, 47, 51]. Mechanistic pathways
to explain the susceptibility of Tregs to CYC includes
downregulated expression of the survival molecule Bcl-xL
and of costimulatory CTLA-4 in CD4+CD25high cells, and
a signiﬁcant decreased production of IL-2 by CD4 eﬀector
cells [4]. The inhibitory eﬀects of low-dose CYC on Tregs are
essential for accomplishing antimyeloma activities, because
coadministration of Tregs 24 hours following the injection
of low-dose CYC (when the cytotoxic eﬀects of the drug were
substantially diminished [46]), to 5T2MM-bearing mice,
abrogated the beneﬁcial eﬀects of CYC on MM [4]. SelectiveBone Marrow Research 5
depletion of Tregs by low-dose CYC resulted in upregulated
numbers of IFN-γ producing NKT cells that are capable
of controlling tumor growth in vivo [60]a n da r ea ﬀected
reciprocally by Tregs [61, 62]. The antitumor properties of
NKTcellsarelinkedtotheirabilitytoproducelargeamounts
of IFN-γ upon activation of NKT cells [63–65]. Further, the
expression of MHC class II and CD86 stimulatory molecules
in DCs was up-regulated, which enhanced their function as
antigen presenting cells [4, 66–68]. Once the concept of low-
dose CYC was proven feasible for potentially enabling an
eﬀective immune response against MM cells, it was essential
to ﬁnd the most eﬀective protocol of treatment by means of
satisfactory and durable antimyeloma eﬀects.
5.2. Optimal Time Schedules of CYC Treatments Aﬀecting
MM Progression. The initial cytotoxic eﬀect of CYC reduced
markedly tumor load, thereby eliminating the acute disease
and prolonging the survival of 5T2MM-bearing mice into a
chronic phase. Further, reduced MM incidence during the
prolonged latency was accomplished by repeated adminis-
trations of low-dose CYC at intervals coinciding with the
timing before complete Treg restoration occurred. Kinetic
studies on Treg depletion and recovery to pretreatment levels
following low-dose CYC injection of 5T2MM-bearing mice
showed that it lasted beyond 45 after CYC administration
[4]. This period of Treg recovery provided a “window of
opportunity” involving a speciﬁc balance between depletion
of Tregs and activation of eﬀector T cell responses resulting
inlysisoftumorcellsandreductionoftumorload(Figure 1).
More frequent administrations of low-dose CYC at 7- or 21-
day intervals did not improve the therapeutic eﬀect, since
these mice developed MM in a higher incidence [4]. These
shorter time intervals limited the “window of opportunity”
by preventing recruitment of eﬀector T cells, NKT, or DCs
required for the reduction of MM incidence. Continuous
low-dose CYC treatments at 45-day intervals were shown
to be most eﬀective in reducing and/or preventing MM
development [4, 59]. Moreover, even when the initial
injection of a high-dose CYC was chosen, further repeated
injections of low-dose CYC at 45-day intervals prevented
the disease [59]. Less frequent administrations of low-dose
CYC enabled recruitment of compatible immune-derived
cells that reduced tumor load and prolonged survival with
minimal residual disease. Thus, issues of doses and schedules
are crucial.
6. Concluding Remarks
The development of MM is associated with humoral and
cellular immune deﬁciencies. Immunological active com-
ponents that promote tumor cell survival are produced by
MM cells. Increased numbers of functional Tregs correlate
with MM progression and severity of disease. Thus, the
eﬀectiveness of antitumor therapy could be enhanced by the
removal of Treg suppressive activity. In this regard, CYC
has a broad antitumor spectrum including lymphoablation
in addition to a direct tumoricidal eﬀect. CYC-induced
disruption of Tregs as a means for reducing the progression
of MM depends on dosing and time schedule of drug
administration. The use of high-dose of CYC is less eﬀective
inpreventingthedisease,sincethecytotoxiceﬀectthenisless
selective, reducing both tumor cells as well as immune cells
with potential antitumor properties. In contrast, treatment
with low-dose CYC is associated with selective Treg deple-
tion, which leads to the restoration of peripheral eﬀector T
cell proliferation and immune function and to a reduction in
MM incidence. Repeated administrations of low-dose CYC
at longer intervals (coinciding with the period of blocked
renewal of Tregs) enable on the one hand the elimination of
tumorcellsandontheotherhandthebreakdownofimmune
tolerance as a result of recovery in eﬀector T cells, NKT cells,
and mature DCs that would react against the residual tumor
cells (Figure 1). The results from preclinical mouse model
present immunological concepts that should be translated to
a clinical setting.
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